Teal Health Raises $22M for At-Home Cervical Screening

Teal Health has successfully closed a $22 million Series A funding round, signaling a significant push to broaden access to its FDA-authorized at-home cervical cancer screening technology. The investment, spearheaded by .406 Ventures, saw continued backing from existing partners Emerson Collective, Forerunner, and Serena Ventures, alongside a new commitment from Japan-based MPower Partners. This capital infusion elevates Teal Health's total funding to $45 million and is earmarked for scaling commercial initiatives, enhancing its technological infrastructure, and bolstering operational capacity across the United States.

The company's innovative Teal Wand offers a speculum-free, at-home method for HPV self-collection, a critical advancement in addressing the persistent gaps in preventive women's healthcare. Nearly one-third of U.S. women are not current with cervical cancer screenings, a statistic Teal Health aims to dramatically improve by removing common barriers such as appointment scheduling difficulties, physician shortages, and the discomfort associated with traditional in-office procedures. The platform integrates the self-collection device with telehealth consultations, secure result delivery, and pathways to necessary follow-up care.

Data from Teal Health indicates a strong resonance with its target demographic, with 59% of users opting for their service being previously underscreened. Since gaining FDA authorization in 2025, the company has facilitated thousands of screenings nationwide, garnering an impressive average patient satisfaction rating of 4.95 out of five. These early metrics underscore the demand for convenient, accessible, and patient-centric preventive health solutions.

This funding round strategically positions Teal Health ahead of significant shifts in healthcare policy. Beginning January 2027, federal guidelines are expected to mandate broader insurance coverage for at-home cervical cancer screening, potentially unlocking widespread adoption. Teal Health is proactively forging distribution partnerships with health insurers, health systems, employers, and healthcare providers to ensure its platform is integrated into existing healthcare ecosystems and benefit plans.

The Series A proceeds will accelerate the development of these crucial commercial relationships, aiming to make screening readily available through channels where women already engage for healthcare and benefits. Beyond insurance-supported avenues, Teal Health is also expanding direct-purchase options, creating a dual approach to reach a wider population. This strategy is vital for establishing at-home HPV testing as a standard component of routine preventive care, moving beyond early adopters.

Further investment will support workforce expansion across clinical, commercial, technology, and operational departments, essential for supporting a growing network of partners and scaling the platform. Teal Health's commitment to evidence-based practice is further demonstrated by its contributions to 17 peer-reviewed publications and presentations on self-collection screening, with its methodology influencing national guidelines. By offering a more accessible screening alternative, Teal Health aims to reduce the burden on clinical facilities and improve outcomes in the fight against cervical cancer, a disease that still accounts for thousands of preventable deaths annually in the U.S.